Long-term survival after pancreaticoduodenectomy for duodenal papillary adenocarcinoma in a patient with acquired immunodeficiency syndrome: A case report and review of literature

Table 1 Results of liver function at admission, preoperation, postoperation, and discharge

Test indication (normal range)1	Admission (day 1)	Preoperation (day 30)	Postoperation (day 31)	Discharge (day 57)
ALB, g/L (35.00-52.00)	40.20	41.60	43.10	41.20
AST, U/L (0-40.00)	89.00	73.00	69.00	25.00
ALT, U/L (0-40.00)	102.00	68.00	51.00	19.00
ALP, U/L (42-140.00)	946.00	760.00	545.00	212.00
GGT, U/L (0-58.00)	1295.00	946.00	797.00	86.00
TBIL, μmol/L (0-26.00)	118.08	32.12	28.63	10.54
DBIL, μmol/L (0-10.00)	85.70	25.40	25.30	5.80
IBIL, μmol/L (0-13.00)	32.40	6.70	3.30	3.30

¹Normal unit range for associated data is within parentheses.

ALB: Albumin; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; ALP: Alkaline phosphatase; GGT: Γ-glutamyl transpeptidase; TBIL: Total bilirubin; DBIL: Direct bilirubin; IBIL: Indirect bilirubin.

Table 2 Dynamics of serum carbohydrate antigen 19-9 levels of the patient

Date of experimentation	Time point	CA19-9, U/mL (0-37.00)1
12 June 2019	Preoperative 1 month	92.40
12 August 2019	Postoperative 1 month	9.46
21 September 2019	Postoperative 2 months	16.38
30 October 2019	Postoperative 3 months	17.52
21 April 2020	Postoperative 9 months	10.60
13 May 2020	Postoperative 10 months	14.04
17 August 2020	Postoperative 13 months	15.21
17 November 2020	Postoperative 16 months	23.20
2 February 2021	Postoperative 19 months	19.51
7 May 2021	Postoperative 22 months	12.54
21 August 2021	Postoperative 25 months	20.23
23 February 2022	Postoperative 31 months	24.23
10 October 2022	Postoperative 39 months	36.94
15 February 2023	Postoperative 43 months	25.48
21 August 2023	Postoperative 49 months	6.38
31 January 2024	Postoperative 54 months	7.19
29 August 2024	Postoperative 61 months	5.69

¹Normal unit range for associated data is within parentheses.

CA 19-9: Carbohydrate antigen 19-9.

Table 3 Cases of people with human immunodeficiency virus undergoing radical resection for gastrointestinal tumors

Ref.	Number of cases	PWH/AIDS	Gender	Age (years)	CD4+ (cells/μL)	Albumin (g/L)	Regular ART treatment	Diagnosis	Treatment	Complications	Follow-up time	Outcome
Sseruwag et al[24], 2023	1	PWH	Female	67	363.00	36.29	Yes	DA	RYGJ + JJ
Salameh et al[25], 2013	1	PWH	Male	39	255.00		No	DA	PGJ + chemotherapy		2 weeks	Survival
Wildi et al[26], 2001	1	PWH	Female	33	100.00		No	PAC	PPPD	No	5 months	Survival
Ramdial et al[27], 2011	1	AIDS	Male	30	168.00	22.00	Yes	PAC	PPD	No	8 months	Survival
Ghatak et al[28], 2013	1	PWH	Female	44	604.00		No	PAC	PD	Gastric emptying delay	3 months	Survival
Hathaway et al[29], 2023	1	PWH	Male	68			No	CC	PD	POPF + pleural effusion
Gandhi et al[30], 2017	1	PWH	Male	40				CC	PD + chemotherapy
Poizot-Martin et al[31], 2018	1	PWH	Male	52	600.00		No	PHC	PD + chemotherapy	No	4 months	Survival
Loots et al[32], 2008	1	PWH	Male	44	123.00	19.00	No	PHC	PD + chemotherapy	Sepsis at wound and drain site	< 3 months	Survival

PWH: People with human immunodeficiency virus; AIDS: Acquired immunodeficiency syndrome; ART: Antiretroviral therapy; DA: Duodenal adenocarcinoma; RYGJ: Roux-en-Y gastrojejunostomy; JJ: Jejunojejunostomy; PGJ: Palliative gastrojejunostomy; PPPD: Pylorus-preserving pancreaticoduodenectomy; PPD: Partial pancreaticoduodenectomy; PD: Pancreaticoduodenectomy; PAC: Periampullary cancer; CC: Cholangiocarcinoma; PHC: Pancreatic head cancer; POPF: Pancreatic fistula.